期刊
SEMINARS IN CANCER BIOLOGY
卷 86, 期 -, 页码 868-874出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2022.02.021
关键词
SCLC; Small cell lung cancer; Immunotherapy; Atezolizumab; Durvalumab
类别
资金
- Alkermes
- Bayer
- Blueprint
- Bristol-Myers Squibb
- Elevation Oncology
- Genentech
- Lilly
- Merck
- Merus
- Pfizer
- Rain Therapeutics
- RAPT
- Turning Point Therapeutics
Immune checkpoint inhibitors have significantly improved the survival outcomes of small cell lung cancer patients when combined with chemotherapy. However, the prognosis for most patients remains poor.
Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly poor prognosis. For decades, the best available systemic therapy was platinum plus etoposide chemotherapy, which offered frequent but transient responses. Survival gains were finally realized with the addition of immune checkpoint inhibitors to first-line chemotherapy. The phase III IMpower 133 trial showed that the addition of atezolizumab to chemo-therapy improved survival. The subsequent CASPIAN trial demonstrated a similar benefit with durvalumab. These results quickly established chemo-immunotherapy as the preferred initial treatment for advanced SCLC, but outcomes remain poor for most patients. Here, we review the current and evolving role of immunotherapy in SCLC and outline emerging strategies poised to further elevate the standard of care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据